11:04 AM EDT, 07/23/2024 (MT Newswires) -- Novo Nordisk's ( NVO ) semaglutide (Wegovy) has been granted a new indication by the UK's Medicines and Healthcare products Regulatory Agency, the agency said Tuesday.

The approval allows Wegovy to be used for reducing cardiovascular risks in overweight and obese adults, the agency said.

Novo Nordisk's ( NVO ) shares were up 0.7% in recent Tuesday trading.

Price: 134.02, Change: +0.84, Percent Change: +0.63